Official Title
Switch or Maintenance of Renin-Angiotensin System Inhibitors in Patients With Covid-19: A Randomized Proof of Concept Trial
Brief Summary

The SWITCH-COVID trial will randomize patients with COVID-19 that are currently using renin-angiotensin system inhibitors for treating hypertension to maintain the therapy during in-hospital stay or switch the therapy to other antihypertensive classes.

Detailed Description

Patients eligible for the study, after signing informed consent will be randomized 1:1 for
maintenance of renin-angiotensin system inhibitors or switching the antihypertensive therapy
for other classes according to a pre-specified protocol.

Patients are going to be followed during hospital stay for evaluation of clinical endpoints.
Also blood and urine samples will be acquired for evaluation of renin-angiotensin system
activation.

Terminated
COVID19
Angiotensin II Receptor Antagonist Adverse Reaction

Drug: Renin-angiotensin system inhibitors

switch anti-hypertensive class

Eligibility Criteria

Inclusion Criteria:

- Hypertension in use of renin-angiotensin system inhibitors

- Confirmed COVID-19 infection by rt-PCR, serology tests or typical clinical
presentation and chest CT.

- Symptoms onset < 96h

- Need for hospitalization

Exclusion Criteria:

- Heart failure

- Previous cerebrovascular disease

- Previous myocardial infarction

- Blood pressure > 180 x 100 mmHg

- Need for 3 or more anti-hypertensive classes

- Use os spironolactone

- Severe pulmonary disease

- Contraindication for using other anti-hypertensive classes (calcium channel blockers,
hydralazine, diuretics or nitrates)

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 80 Years
Countries
Brazil
Locations

Instituto do Coração - Incor HCFMUSP
São Paulo, SP, Brazil

University of Sao Paulo
NCT Number
Keywords
COVID19
ace inhibitors
ACE2
MeSH Terms
COVID-19